BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development UnderwayVANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce continued progress in its sublingual Semaglutide oral dissolvable film ("ODF") program, marking the next stage of development for the Company's GLP-1 delivery platform.
